Sponsored

Prescient Therapeutics (ASX:PTX) to progress deep cancer-treatment pipeline with capital raise

August 26, 2022 10:02 AM AEST | By Aditi Sarkar
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Prescient intends to raise AU$8.0 million via a Share Purchase Plan (SPP)
  • Funds from the SPP will be used to develop the company’s pipeline of innovative cancer therapies and for general working capital.
  • New fully paid ordinary shares will be distributed at $0.175 apiece.

Clinical-stage oncology firm Prescient Therapeutics (ASX: PTX) announces a Share Purchase Plan (SPP) to raise AU$8.0 million.

Funds raised from the SPP will be used for the following:

  • Clinical development of PTX-100 and PTX-200 targeted therapies
  • Progressing its innovative cell therapies, OmniCAR and CellPryme-M, towards and into first-inhuman clinical studies
  • General working capital and expenses of the offer

Prescient Advancing New Cancer Therapies with A Leading Team of Global Cancer Specialists

*Eligible shareholders - Registered shareholders as at 5:00pm (AEST) on Tuesday 23rd August 2022 (Record Date).

Indicative timetable of key dates for the SPP

Payment deadline: 5pm (AEST) on Wednesday, 28 September 2022.

Commenting on the SPP, the company’s CEO & Managing Director, Steven Yatomi-Clarke said that Prescient is seeking to maintain the momentum and position in the oncology space gained by the company during the last few years. He further added that the company is working to develop a diverse and groundbreaking pipeline of personalised therapies for cancer.

For more on SPP

Shareholders can find more information on Prescient’s SPP by clicking here.

To know more about Prescient Therapeutics Limited, click here. Also, to stay updated with PTX company activities and announcements, please update your details on their investor centre.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.